NCT05120362

A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash

An Investigator-initiated Trial to Evaluate the Efficacy and Safety of JAK Inhibitor Cream for the Treatment of EGFR-inhibitor-induced Skin Rash

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Shanghai East Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Epidermal growth factor receptor inhibitors (EGFRIs) are widely used targeted agents that have been approved for the treatment of various tumor types. In some clinical studies with EGFRIs, the incidence of dermatology AE, the skin rash, is reportedly as high as 95%, which profoundly impact the patients' quality of life. However no treament for onset skin rash has been approved to be effective by any clinical trial yet. Janus kinase (JAK) inhibitor, has been approved for or studied in a variety of skin conditions such as alopecia areata, atopic dermatitis, and psoriasis. Thus the investigators intend to evaluate the efficacy and safety of JAK inhibitor cream for the treatment of EGFRIs-induced skin rash in cancer patients.

Conditions

• Acneiform Eruptions

Interventions

Type	Name	Description
DRUG	Cream containing JAK Inhibitor	The study drug is a cream containing JAK Inhibitor.

Timeline

• Start date: 2021-11-03
• Primary completion: 2023-03-31
• Completion: 2023-04-30
• First posted: 2021-11-15
• Last updated: 2023-03-02

Locations

1 site across 1 country: China